# Efficacy of an Intranasal Testosterone Product

> **NCT01252745** · PHASE2 · COMPLETED · sponsor: **Acerus Pharmaceuticals Corporation** · enrollment: 22 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** 10.0 mg of Testosterone, 4.0% TID
- **DRUG:** 13.5 mg of Testosterone, 4.5% B.I.D
- **DRUG:** 11.25 mg of Testosterone, 4.5% T.I.D

## Key facts

- **NCT ID:** NCT01252745
- **Lead sponsor:** Acerus Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2010-11
- **Final completion:** 2010-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01252745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01252745, "Efficacy of an Intranasal Testosterone Product". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01252745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*